Lonza price target raised to CHF 670 from CHF 650 at RBC Capital
RBC Capital analyst Charles Weston raised the firm's price target on Lonza to CHF 670 from CHF 650 and keeps an Outperform rating on the shares.
Lonza Group AG Non-GAAP EPS of CHF 7.28, revenue of CHF 2.98B; reaffirms FY22 guidance
Lonza Group AG press release (OTCPK:LZAGY): 1H Non-GAAP EPS of CHF 7.28. Revenue of CHF 2.98B (+17.3% Y/Y). Lonza reconfirms Outlook for Full-Year 2022: Low to mid-teens CER sales growth; CORE EBITD
Lonza price target lowered to CHF 700 from CHF 750 at Credit Suisse
Credit Suisse analyst Trung Huynh lowered the firm's price target on Lonza to CHF 700 from CHF 750 and keeps an Outperform rating on the shares.
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field
Galapagos (NASDAQ:GLPG) agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities.
Lonza finishes laboratory expansion at API manufacturing facility in China
Lonza (OTCPK:LZAGY) (OTCPK:LZAGF) completed laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site in Nansha, China. The company said the expansion , which grew the lab
Lonza to make HaemaLogiX's multiple myeloma drug KappaMab for clinical trials
Lonza (OTCPK:LZAGY) signed an agreement to manufacture the next clinical batch of HaemaLogiX's lead multiple myeloma drug candidate KappaMab. Under the agreement, Lonza will manufacture drug substance
Lonza Group AG GAAP EPS of CHF39.52, revenue of CHF5.4B
Lonza Group AG press release (OTCPK:LZAGY): FY GAAP EPS of CHF39.52.Revenue of CHF5.4B (+20.0% Y/Y).
Lonza price target raised to CHF 900 from CHF 850 at JPMorgan
JPMorgan analyst Richard Vosser raised the firm's price target on Lonza to CHF 900 from CHF 850 and keeps an Overweight rating on the shares.
KeyBanc lists beneficiaries in life sciences as Omicron drives demand for PCR tests, vaccines
A group of analysts from KeyBank Capital Markets has named several life sciences companies that could benefit from renewed demand for PCR tests and COVID-19 vaccines after the emergence of the newly
Lonza to Acquire Service Unit in Italy, Manufacturing Facility in US
By Cecilia Butini Lonza Group AG said Tuesday that it has acquired a service unit including laboratories in Italy and a manufacturing facility in the U.S. The Swiss life-sciences company s